VuCOMP

The company's main product line included M-Vu CAD and M-Vu Breast Density software. M-Vu CAD utilized sophisticated mathematical algorithms to analyze mammograms and mark potential areas of concern for radiologists to review. A key feature of this system was the use of SmartMarks, which were annotations that outlined detected regions without obscuring underlying structures. The M-Vu CAD system was notable for being the first to meet a rigorous FDA standard that required comprehensive reader studies to prove its effectiveness in assisting radiologists. The M-Vu Breast Density software was designed to measure breast tissue density, a factor that can mask the presence of cancer. These products were compatible with digital mammography systems from major manufacturers like GE, Hologic, Siemens, and Philips, providing a unified solution for clinics with diverse equipment.

VuCOMP's business model centered on the development and sale of this licensed software to clinics and medical imaging providers. The company demonstrated a commitment to continuous improvement, regularly releasing software updates to enhance performance, such as by reducing false positive rates and increasing detection sensitivity, at no additional cost to its customers. Throughout its history, VuCOMP achieved significant milestones, securing multiple U.S. Food and Drug Administration (FDA) approvals and market clearances for various versions of its M-Vu software, including in Canada and Turkey. In a strategic move to focus resources on developing CAD for breast tomosynthesis, VuCOMP sold its M-Vu Breast Density software to iCAD, Inc. in April 2015. This was followed by the acquisition of VuCOMP's entire cancer detection portfolio, including the M-Vu CAD platform, key personnel, and its customer base, by iCAD in January 2016.